In the Lab
Clearing the Fog around Tumor Mutational Burden
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
One Patient’s Exceptional Response Leads to a Surprising Discovery about Immunotherapy
MSK researchers learn that some cancers may respond to checkpoint inhibitor drugs because of changes called gene fusions.
Tumor Mutational Burden Can Help Predict Response to Immunotherapy in Many Different Cancers
Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.